Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Suspension of Manufacturing, Import of Products Using Bovine-Derived Ingredients Originating in Norway
February 4, 2015
- Dr Fukui of St. Luke’s Tapped as Health Sciences Council Chair
February 3, 2015
- MHLW Compiles Requirements for Legally Recognized Clinical Research Core Hospitals
February 3, 2015
- Review Time Targets for New Drugs Revised: PFSB
February 3, 2015
- NIID to Evaluate Prototype Strains for Cell Culture-Based Influenza Vaccines
February 3, 2015
- MHLW Orders Package Insert Revision for Zytiga to Include Hypokalemia as Significant Adverse Reaction
February 3, 2015
- Wholesalers Settled FY2014 Drug Prices with 70% of Customers at December-End: Official
February 2, 2015
- PAFSC First Committee Backs Approval of Takeda’s Once-Weekly DPP-4 Inhibitor
February 2, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- Drug Wholesalers Should Stress Annual Price Cuts “Infeasible”: Ex-Minister
January 30, 2015
- MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel
January 30, 2015
- Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
- Expenditure for Senshin-Iryo Services Totaled 17.4 Billion Yen: MHLW
January 29, 2015
- Chuikyo Approves Insurance Reimbursement for Companion Diagnostic for Zelboraf
January 29, 2015
- Government Releases Strategy for Dementia
January 28, 2015
- Prof. Hashida of Kyoto University Elected as PAFSC Chairman
January 28, 2015
- Panel OKs Requirements to Give Legal Status to Clinical Research Core Hospitals
January 27, 2015
- Panel on Unapproved Drugs Weighs Revamp upon Rollout of New Development Request Scheme
January 27, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…